<DOC>
	<DOCNO>NCT02213263</DOCNO>
	<brief_summary>This study compare safety effectiveness PF-05280586 versus rituximab-EU patient CD20-positive , low tumor burden follicular lymphoma . The primary hypothesis test study effectiveness PF-05280586 , measure Overall Response Rate , similar rituximab-EU .</brief_summary>
	<brief_title>A Study Of PF-05280586 ( Rituximab-Pfizer ) Or MabTheraÂ® ( Rituximab-EU ) For The First-Line Treatment Of Patients With CD20-Positive , Low Tumor Burden , Follicular Lymphoma ( REFLECTIONS B328-06 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Confirmed diagnosis low tumor burden , CD20positive follicular lymphoma Ann Arbor Stage II , III , IV Not candidate treatment rituximab singleagent Evidence transformation high grade diffuse large Bcell lymphoma Any previous systemic therapy Bcell NHL , include chemotherapy , immunotherapy , steroids Any prior treatment rituximab Active , uncontrolled infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>rituximab</keyword>
	<keyword>follicular lymphoma</keyword>
	<keyword>Non-Hodgkin lymphoma</keyword>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
</DOC>